Patent intelligence · US
US 11701354
Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors
Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors
Patent details — US 11701354
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 18, 2023
- Expiration
- Jul 13, 2043
- Applicant
- Relay Therapeutics, Inc.
- Claims
- 40
- CPC classes
- A61K, A61K31/4985, A61K45/06, A61P
Quick answer
US 11701354 (Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors) is held by Relay Therapeutics, Inc.. Status: granted. Granted Jul 18, 2023. Expires Jul 13, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Relay Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 40
- CPC classes
- A61K, A61K31/4985, A61K45/06, A61P, A61P3/00, A61P35/00
More from Relay Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12331056
SHP2 phosphatase inhibitors and methods of use thereof
granted -
US 12219327
Substituted isoindolines as PI3K-alpha inhibitors
granted -
US 12152034
FGFR inhibitors and methods of making and using the same
granted -
US 12138263
Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof
granted -
US 12084447
SHP2 phosphatase inhibitors and methods of use thereof
granted -
US 11890281
SHP2 phosphatase inhibitors and methods of making and using the same
granted -
US 11780845
FGFR inhibitors and methods of use thereof
granted
Frequently asked questions
What is US patent 11701354?
US 11701354 (Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors) is held by Relay Therapeutics, Inc.. Status: granted. Granted Jul 18, 2023. Expires Jul 13, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11701354?
Relay Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does US 11701354 expire?
Our index shows an expiration date of Jul 13, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.